

Technology Advisory Committee C Interests Register

Topic [ID5085]

Publication Date: 04/09/2024

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Dr Richard Nicholas	Committee Member	Direct - Financial	Dr Nicholas has carried paid advisory boards for Roche and Novartis in an unrelated disease area (multiple sclerosis).	16/04/2024	It was agreed that Dr Nicholas' declaration would not prevent him from participating in discussions on this appraisal.
Michael Chambers	Committee Member	Direct - Financial	Michael Chambers is a member of an advisory panel for Pfizer (a possible comparator company) in an unrelated disease area (prostate cancer).	15/04/2024	It was agreed that Michael's declaration would not prevent him from participating in discussions on this appraisal.
Satish Venkateshan	Committee Member	Direct - Financial	Regeneron is developing therapeutics for a broad range of diseases including various types of lymphomas and other haematologic malignancies. Satish works for Regeneron, a pharmaceuticals/biotech company. He also owns shares in the company and has stock options.	18/04/2024	It was agreed that Satish's declaration would not prevent him from participating in discussions on this appraisal.
Dr Kate Ren	Committee Member	Direct - Financial	Dr Ren attended a paid advisory board meeting for zanubrutinib in relapsed/refractory marginal zone lymphoma (MZL).	15/04/2024	It was agreed that Kate's declaration would prevent her from participating in discussions on this appraisal.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Dr Kim Linton	Clinical Expert	Direct - Financial	<ul style="list-style-type: none"> Dr Linton received consultancy fees from BeiGene for participation in an advisory board. Dr Linton received an honorarium from NICE for participating in the zanubrutinib OMA. 	24/10/2023	It was agreed that Dr Linton's declaration would not prevent her from providing expert advice to the committee.
Dr Renata Walewska	Clinical Expert	Direct - Financial	Dr Walewska has received speaker and advisory board fees from BeiGene, Jansen, AstraZeneca, and AbbVie.	06/12/2023 07/05/2024	It was agreed that Dr Walewska's declaration would not prevent her from providing expert advice to the committee.
Frank Burroughs	Patient Expert	Direct – Financial	Frank's nominating organisation, Lymphoma Action, has received funding from BeiGene, Pfizer, and Roche.	06/10/2023	It was agreed that Frank's declaration would not prevent him from providing expert advice to the committee.